Results from C. difficile test in less than 30 minutes

The US firm Inverness Medical has launched a new rapid test as an in vitro diagnostic aid for Clostridium difficile associated disease (CDAD).

Photo: Results from C. difficile test in less than 30 minutes

Named the Techlab C. Diff Quik Chek Complete, the test detects glutamate dehydrogenase (GDH) and C. difficile toxins A and B in one simple assay, and can be used for screening while confirming the presence of toxigenic C. difficile strains, Inverness reports. C. difficile antigen glutamate dehydrogenase (GDH) is common to all C. difficile strains and has been identified as an excellent screening marker for the infection.
Results from faecal samples are provided in less than 30 minutes, enabling rapid diagnosis, patient management and isolation at an earlier stage, to reduce further contaminations.
The new test also detects toxigenic and non-toxigenic strains, including the new hyper-virulent C. difficile strain BI/NAP1/027 that is causing outbreaks of increasing severity and mortality across Europe and North America, the firm points out.
Regulatory clearances are now in process for use in the USA and Canada.

19.11.2008

More on the subject:

Related articles

Photo

News • Ependymoma and medulloblastoma tumoroids

New organoids offer deeper insights into pediatric brain cancer

Patient-derived organoids (PDOs), or tumoroids, for pediatric brain cancer show promise in helping researchers find new drugs and better understand the different responses of the tumor.

Photo

News • Dynamic in vitro platform

“Breathing” organoid offers new insights into lung disease

A new type of “breathing” lung organoid enables quantitative measurement of how easily the lung expands - and may provide a new way to study diseases such as pulmonary fibrosis.

Photo

News • Neurodegenerative diseases

New biomarker improves diagnosis of Parkinson's and LBD

A biomarker discovered in the cerebrospinal fluid could improve diagnosis of Parkinson's disease and dementia with Lewy bodies.

Subscribe to Newsletter